SEC Form 4 · accession 0002123975-26-000021
BioNTech SE · BNTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ugur Sahin
Officer — Chief Executive Officer · 10% Owner
Period of report
Sep 21, 2026
Accepted (ET)
Sep 22, 2026 · 5:04 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001776985
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Sep 21, 2026 | S | 33,000 | $97.8097 | D | 456,209 | D | |
| Ordinary Shares | Sep 22, 2026 | S | 46,000 | $100.7182 | D | 410,209 | D | |
| Ordinary SharesF1 | holding | — | — | — | 39,218,111 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The ordinary shares are held by Medine GmbH. The reporting person is the sole shareholder of Medine GmbH. 106,721 of the ordinary shares noted herein are held for the benefit of an individual under a trust arrangement, pursuant to which Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust. The reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH.
Remarks
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on June 3, 2026.